How Investors May Respond To Edgewise Therapeutics (EWTX) Long-Term Sevasemten Data at World Muscle Congress [Yahoo! Finance]
Edgewise Therapeutics, Inc. (EWTX)
Company Research
Source: Yahoo! Finance
muscular dystrophies, at the 30th Annual Congress of the World Muscle Society in Vienna on October 8, 2025. This update, featuring data from the CANYON and MESA trials showing disease stabilization, could impact how future Phase 3 studies are planned and how regulatory agencies evaluate sevasemten. We'll explore how the presentation of robust long-term data for sevasemten may shape Edgewise Therapeutics' investment outlook and regulatory discussions. The end of cancer? These 28 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. What Is Edgewise Therapeutics' Investment Narrative? For anyone considering Edgewise Therapeutics, the big picture is about believing in the promise of its pipeline, especially the potential of sevasemten to address Becker and Duchenne muscular dystrophies. The long-term CANYON and MESA trial results shared at the World Muscle Society Congress fit squarely into the company
Show less
Read more
Impact Snapshot
Event Time:
EWTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EWTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EWTX alerts
High impacting Edgewise Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
EWTX
News
- Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesPR Newswire
- Edgewise Therapeutics (NASDAQ:EWTX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=EWTX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
- Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of DirectorsPR Newswire
- Will Edgewise Therapeutics' (EWTX) New CFO Mark a Shift in Its Commercial Strategy? [Yahoo! Finance]Yahoo! Finance
EWTX
Earnings
- 11/6/25 - Beat
EWTX
Sec Filings
- 11/24/25 - Form 4
- 11/24/25 - Form 3
- 11/20/25 - Form 8-K
- EWTX's page on the SEC website